Rena M. Conti, PhD is currently an Associate Research Director in BioPharma and Public Policy at the Institute for Health System Innovation and Policy at Boston University.
She is also an Associate Professor of Markets, Public Policy, and Law. Dr. Conti is a 2007 graduate of the Harvard University Interfaculty Initiative in health policy and an elected member of the Conference on Research on Income and Wealth. She formerly was Associate Professor, Departments of Pediatrics and Public Health Sciences, Biological Sciences Division and the Harris School of Public Policy at the University of Chicago.
Dr. Conti’s research is on the financing, organization and regulation of medical care. She is an expert on the demand for, supply of and pricing of prescription drugs, particularly those used to treat cancer and other “specialty” conditions. She has published over 50 peer reviewed studies on what factors determine the pricing of branded and generic prescription drugs, the intended and unintended consequences of the 340B drug discount program and the evolving supply of generic drugs including the causes and consequences of drug shortages. She is interested in using classic economic theory to guide policy making on the expansion of new drug development and patient access to existing drugs. Dr. Conti is a frequent ad hoc advisor to health systems, biopharmaceutical innovators and investors and policy makers on these and related concerns.